Literature DB >> 18922940

Sphingosine kinase 1: a new modulator of hypoxia inducible factor 1alpha during hypoxia in human cancer cells.

Isabelle Ader1, Leyre Brizuela, Pierre Bouquerel, Bernard Malavaud, Olivier Cuvillier.   

Abstract

Here, we provide the first evidence that sphingosine kinase 1 (SphK1), an oncogenic lipid kinase balancing the intracellular level of key signaling sphingolipids, modulates the transcription factor hypoxia inducible factor 1alpha (HIF-1alpha), master regulator of hypoxia. SphK1 activity is stimulated under low oxygen conditions and regulated by reactive oxygen species. The SphK1-dependent stabilization of HIF-1alpha levels is mediated by the Akt/glycogen synthase kinase-3beta signaling pathway that prevents its von Hippel-Lindau protein-mediated degradation by the proteasome. The pharmacologic and RNA silencing inhibition of SphK1 activity prevents the accumulation of HIF-1alpha and its transcriptional activity in several human cancer cell lineages (prostate, brain, breast, kidney, and lung), suggesting a canonical pathway. Therefore, we propose that SphK1 can act as a master regulator for hypoxia, giving support to its inhibition as a valid strategy to control tumor hypoxia and its molecular consequences.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18922940     DOI: 10.1158/0008-5472.CAN-08-0917

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  61 in total

1.  Genome-wide identification of TAL1's functional targets: insights into its mechanisms of action in primary erythroid cells.

Authors:  Mira T Kassouf; Jim R Hughes; Stephen Taylor; Simon J McGowan; Shamit Soneji; Angela L Green; Paresh Vyas; Catherine Porcher
Journal:  Genome Res       Date:  2010-06-21       Impact factor: 9.043

2.  Inhibition of sphingosine kinase 1 suppresses proliferation of glioma cells under hypoxia by attenuating activity of extracellular signal-regulated kinase.

Authors:  H Zhang; W Li; S Sun; S Yu; M Zhang; F Zou
Journal:  Cell Prolif       Date:  2012-01-30       Impact factor: 6.831

Review 3.  p53 and regulation of bioactive sphingolipids.

Authors:  Linda A Heffernan-Stroud; Lina M Obeid
Journal:  Adv Enzyme Regul       Date:  2010-10-28

4.  Sphingosine kinase-2 inhibition improves mitochondrial function and survival after hepatic ischemia-reperfusion.

Authors:  Yanjun Shi; Hasibur Rehman; Venkat K Ramshesh; Justin Schwartz; Qinlong Liu; Yasodha Krishnasamy; Xun Zhang; John J Lemasters; Charles D Smith; Zhi Zhong
Journal:  J Hepatol       Date:  2011-07-12       Impact factor: 25.083

5.  Sphingosine kinase 1 and sphingosine-1-phosphate in oxidative stress evoked by 1-methyl-4-phenylpyridinium (MPP+) in human dopaminergic neuronal cells.

Authors:  Joanna Pyszko; Joanna B Strosznajder
Journal:  Mol Neurobiol       Date:  2014-01-09       Impact factor: 5.590

Review 6.  Hypoxia-Induced Signaling Promotes Prostate Cancer Progression: Exosomes Role as Messenger of Hypoxic Response in Tumor Microenvironment.

Authors:  Gagan Deep; Gati K Panigrahi
Journal:  Crit Rev Oncog       Date:  2015

Review 7.  Endothelial cell metabolism in health and disease: impact of hypoxia.

Authors:  Brian W Wong; Elke Marsch; Lucas Treps; Myriam Baes; Peter Carmeliet
Journal:  EMBO J       Date:  2017-06-21       Impact factor: 11.598

8.  Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.

Authors:  Jagadish Kummetha Venkata; Ningfei An; Robert Stuart; Luciano J Costa; Houjian Cai; Woodrow Coker; Jin H Song; Kiwana Gibbs; Terri Matson; Elizabeth Garrett-Mayer; Zhuang Wan; Besim Ogretmen; Charles Smith; Yubin Kang
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

9.  Tumor-suppressive sphingosine-1-phosphate receptor-2 counteracting tumor-promoting sphingosine-1-phosphate receptor-1 and sphingosine kinase 1 - Jekyll Hidden behind Hyde.

Authors:  Noriko Takuwa; Wa Du; Erika Kaneko; Yasuo Okamoto; Kazuaki Yoshioka; Yoh Takuwa
Journal:  Am J Cancer Res       Date:  2011-02-16       Impact factor: 6.166

10.  Metabolic signature identifies novel targets for drug resistance in multiple myeloma.

Authors:  Patricia Maiso; Daisy Huynh; Michele Moschetta; Antonio Sacco; Yosra Aljawai; Yuji Mishima; John M Asara; Aldo M Roccaro; Alec C Kimmelman; Irene M Ghobrial
Journal:  Cancer Res       Date:  2015-03-13       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.